Patent Grant
8486060
This invention relates to a medical procedure.
Ablation of the interior lining of a body organ is a procedure that involves heating the organ lining to temperatures that destroy the cells of the lining or coagulate tissue proteins for hemostasis. Such a procedure may be performed as a treatment to one of many conditions, such as chronic bleeding of the endometrial layer of the uterus or abnormalities of the mucosal layer of the gallbladder. Existing techniques for effecting ablation include circulation of heated fluid inside the organ (either directly or inside a balloon), laser treatment of the organ lining, and resistive heating using application of RF energy to the tissue to be ablated.
An example of resistive heating using application of RF energy to the tissue is described in U.S. Pat. No. 5,769,880, entitled “Moisture Transport System for Contact Electrocoagulation”, issued to Truckai, et al, on Jun. 23, 1998. A system for transporting moisture away from the ablation site is described therein. A build-up of fluid at the ablation site can decrease impedance at the electrode/tissue interface effecting the depth of tissue destruction and efficiency of the procedure.
In some prior art RF devices, fluid drawn from the tissue creates a path of conductivity through which current traveling through the electrodes will flow. This can prevent the current from traveling into the tissue to be ablated. Moreover, the presence of this current path around the electrodes causes current to be continuously drawn from the electrodes. The current heats the liquid drawn from the tissue and thus turns the ablation process into a passive heating method in which the heated liquid around the electrodes causes thermal ablation to continue well beyond the desired ablation depths.
The invention described herein relates to a medical procedure. In general, in one aspect, the invention features a method for tissue ablation. An RF applicator including an electrode carrier with one or more bipolar electrodes thereon is positioned at a target tissue site for tissue ablation. A current at an initial current level is passed through the one or more bipolar electrodes to the target tissue site to apply an initial power density to destroy tissue for an initial time period. A vacuum source in fluid communication with the RF applicator is employed to remove moisture generated during ablation away from the target tissue site. After the initial time period, the power density is ramped up by increasing the current passed through the one or more bipolar electrodes to the target tissue site for a second time period.
Implementations of the invention can include one or more of the following features. Ramping up the power density can include steadily increasing the current over the second time period. Alternatively, ramping up the power density can include suddenly increasing the current from the initial current level to a second current level and applying the second current level for the second time period. The method can further include monitoring an impedance level at an interface between the target tissue site and the RF applicator, where the initial time period is a time period after which a threshold decrease in the impedance level from an initial impedance level is detected. The second time period can be a time period beginning when the threshold decrease in impedance level is detected and ending when the impedance level is detected as having returned to substantially the initial impedance level. After the second time period, the power density can be decreased to the initial power density. In one implementation, after decreasing the power density to the initial power density, the power density can be steadily increased over a third time period.
In one implementation, the target tissue site is a tubal ostium in a female uterine cavity, the initial power density is approximately 5 watts per square centimeter, the decrease in impedance level detected is a decrease of approximately 25%, and the power density is increased during the second time period at a rate of approximately 1 watt per square centimeter per second. In another implementation, the target tissue site is a tubal ostium in a female uterine cavity, the initial power density is approximately 5 watts per square centimeter, the decrease in impedance level detected is a decrease of approximately 33%, and the power density is increased during the second time period at a rate of approximately 2.5 watts per square centimeter per second. In yet another implementation, the target tissue site is a tubal ostium in a female uterine cavity, the initial power density is approximately 5 watts per square centimeter, the decrease in impedance level detected is a decrease of approximately 50%, and the power density is increased during the second time period to a level of approximately 10 to 15 watts per square centimeter.
The initial time period can be determined empirically as a time period after which an initial depth of tissue destruction has been achieved. In one implementation, the target tissue site is a tubal ostium in a female uterine cavity, the initial power density is approximately 5 watts per square centimeter, the initial time period is between approximately 45 and 60 seconds, the power density is increased during the second time period at a rate of approximately 1 watt per square centimeter per second, and the second time period is between approximately 5 and 10 seconds. In another implementation, the target tissue site is a tubal ostium in a female uterine cavity, the initial power density is approximately 5 watts per square centimeter, the initial time period is between approximately 10 and 60 seconds, the power density is increased during the second time period at a rate of approximately 0.5 to 2.5 watts per square centimeter per second, and the second time period is between approximately 5 and 10 seconds.
Implementations of the invention can feature one or more of the following advantages. The techniques for controlling the power density to an ablation site provide the benefit of starting out with a power density low enough to obtain the desired depth of ablation, while ramping up the power density at the appropriate time to address any fluid migration that may occur as the ablation progresses.
The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.
Like reference symbols in the various drawings indicate like elements.
A technique for tissue ablation using resistive heating and a moisture transport system is described. An RF applicator including an electrode carrier with one or more bipolar electrodes thereon is positioned at a target tissue site for tissue ablation. A current at an initial current level is passed through the one or more bipolar electrodes to the target tissue site to apply an initial power density to destroy tissue for an initial time period. A vacuum source in fluid communication with the RF applicator is employed to remove moisture generated during ablation away from the target tissue site. After the initial time period, the power density is ramped up by increasing the current passed through the one or more bipolar electrodes to the target tissue site. The ramped up power is applied for a second time period.
Because, even with the vacuum source employed, fluid can migrate into the region of the electrode/tissue interface, impedance levels at the interface can drop. If the excess fluid is not removed, it may create a path of conductivity through which the current traveling through the electrodes will flow. This can prevent the current from traveling into the tissue to be ablated. Moreover, the presence of this current path around the electrodes can cause current to be continuously drawn from the electrodes. The current heats the liquid drawn from the tissue and thus can turn the ablation process into a passive heating method, in which the heated liquid around the electrodes causes thermal ablation to continue well beyond the desired ablations depths.
Power density is inversely proportional to the depth of tissue destruction. As such, a relatively low power density is generally used to achieve desired depths of destruction. Ablated tissue becomes dehydrated and therefore decreases in conductivity. By shunting moisture away from the ablation site and preventing fluid build-up, a fluid conductor at the ablation area during use of the ablation device can be avoided. When ablation reaches a desired depth, the impedance at the electrode/tissue interface becomes sufficiently high to stop or nearly stop the flow of current into the tissue. The RF ablation thereby stops and thermal ablation does not occur in significant amounts. By equipping the RF generator with an impedance monitor, the operator of the ablation device can monitor the impedance at the electrode/tissue interface and will know that ablation has self-terminated once the impedance rises to a certain level and then remains fairly constant. In one implementation, the RF generator can be configured to automatically shut-off RF power once the impedance rises to the certain level.
However, in some ablation procedures, it can be difficult to avoid fluid migration into the ablation area, even with the use of a moisture transport system. If excess fluid does migrate into the electrode/tissue interface region, ramping up the power density is an effective way to handle the excess fluid and drive up the tissue impedance. A higher power density can vaporize the fluid easily and recover the impedance signal, whereas a lower power density can languish, unable to manage the fluid in a timely fashion, leading to abnormally long procedure times and tissue destruction deeper than desired. Techniques are described herein for determining at what point in an ablation procedure to ramp up power density to deal with excess fluid, while still achieving the desired depth of destruction.
In one implementation, a time-based function is used. That is, after a pre-determined initial time period the power density is increased, either suddenly or gradually, and the increased (or increasing) power density is applied for a second time period. In one implementation, the initial and second time periods can be determined empirically. For example, an initial power density can be applied to an experimental target tissue site for varying time periods, a fluid is then intentionally introduced into the target tissue site and the power density ramped by varying amounts for varying time periods. By experimenting with the initial time period, initial power density, power ramp up and second time period, while monitoring the depth of tissue destruction, the desired time periods and power levels can be determined.
In another implementation, an impedance-based function is used. That is, the impedance at the electrode/tissue interface is monitored. Upon detecting a decrease in the impedance by a threshold amount, which can indicate the presence of a fluid layer, the power density can be ramped up either suddenly or gradually. A sudden ramp-up is generally preferred for a sudden, relatively large drop in impedance, while a gradual ramp-up is preferred otherwise, as shall be described in further detail below.
The power ramping techniques described herein can be used in various tissue ablation procedures. For illustrative purposes, one implementation involving tissue ablation in the region of a tubal ostium in a female for the purpose of fallopian tubal occlusion is described. A medical device to perform the procedure includes an RF applicator head configured to position within the tubal ostium. Examples of such medical devices are described in U.S. patent application Ser. No. 11/019,580, entitled “Method and System for Transcervical Tubal Occlusion”, filed Dec. 20, 2004, by Sampson, et al and in U.S. patent application Ser. No. 11/532,886, entitled “Curved Endoscopic Medical Device”, filed Sep. 18, 2006, by Sampson et al, and the entire contents of both applications are hereby incorporated by reference. To illustrate the techniques for power ramping described herein, reference shall be made to medical devices configured for tubal occlusion, however, the power ramping techniques are not limited to such a medical procedure and can be applied in other ablation procedures.
Referring to
The ablation device 105 generally includes three major components: a handle 140, a curved shaft 145, and a radio frequency (RF) applicator head 150. The curved shaft 145 includes a distal end 155, a proximal end 160, and a hollow central interior 165. The curved shaft 145 is a substantially rigid member configured with a curve to facilitate the advancement of the distal end 155 through a body cavity to a region of tissue to be ablated. The central interior 165 of the curved shaft 145 can include one or more lumens. For example, in one implementation, the central interior 165 includes a lumen that can be operated so as to couple a vacuum source to the RF applicator head 150. The application of vacuum can be used to draw moisture away from one or more electrodes included in the RF applicator head 150 at the electrode/tissue interface.
Additionally, a lumen (either the same lumen that couples to a vacuum source or a different lumen) can be configured to receive a curved hysteroscope. Further, the handle 140 is configured to couple the ablation device 105 to the curved hysteroscope, which is received via a port 170, and to a coupling assembly to couple the ablation device to a controller.
The RF applicator head 150 is positioned at the distal end 155 of the curved shaft 145 and includes an electrode carrier having one or more bipolar electrodes. One or more electrical conductors extend from the RF applicator head 150 to the proximal end 160 of the curved shaft 145 and electrically couple the RF applicator head 150 to a controller. The controller can be operated so as to control the delivery of RF energy to the one or more bipolar electrodes.
In the particular implementation shown in
The RF applicator head 150 is introduced transcervically into the uterine cavity and positioned at a tubal ostium 135. Transmitting RF energy through the RF applicator head 150 ablates the uterine tissue 120, 125 and the tissue within the tubal ostium 135. Following the destruction of the tissue at the tubal ostium 135, the healing response occludes the tubal ostium 135 and the adjacent portion of the fallopian tube 130 resulting in sterilization.
Tissue ablation can occur by positioning the RF applicator head 150 at a target tissue site and by passing a current at an initial current level through the one or more bipolar electrodes in the RF applicator head 150 to the target tissue site. The current is passed at an initial current level to the target tissue site such that the tissue is destroyed by applying an initial RF power density for an initial (i.e., first) time period. As the tissue is destroyed by the RF energy, fluid is released by the tissue undergoing ablation. The moisture can be withdrawn from the electrode/tissue interface by the application of vacuum. However, fluid may migrate from another area of the uterine cavity or bleeding near the region may occur. Thus, even with the application of vacuum, over time a layer of fluid can form near the electrodes and decrease the impedance level at the electrode/tissue interface. Increasing the RF power density can help to vaporize the excess fluid thereby increasing the impedance. Ramping up the RF power density can be either abrupt or gradual.
In one embodiment, ramping up the RF power density includes steadily or gradually increasing the current over the second time period. Determining when to begin the power ramp-up, i.e., determining the value of the initial time period, and the amount by which to ramp-up, as mentioned above in one implementation is according to a time-based function and in another implementation is according to an impedance-based function. Referring to
The duration of the first time period 210, i.e., n seconds, is a time after which the impedance level at the electrode/tissue interface decreases to a threshold impedance of Z1 or by a threshold percentage level to Z1. As discussed above, the value of “n” can be determined either empirically, e.g., by experimentation, or by monitoring the impedance at the electrode/tissue interface. In either case, once the threshold impedance Z, has been reached, the power density is ramped up to vaporize excess fluid that has likely migrated to the electrode/tissue interface and caused the decrease in impedance. The RF power density applied for the duration of the second time period 215 is ramped up at a constant rate from PD1 to PD2. The rate of RF power density increase in the implementation shown can be calculated as: (PD2−PD1)/(t2−t1).
The impedance profile 255 of
By way of illustration, in the context of tissue ablation for the purpose of tubal occlusion, the values of power density relative to the monitored impedance level when carrying out the implementation shown in
In the implementation depicted in
In a more specific example, the initial RF power density is approximately 5 watts/cm2 and the initial time period is between approximately 45 and 60 seconds. After the first time period, and for the duration of the second time period, the RF power density is increased at a rate of approximately 1 watt/cm per second. The duration of the second time period is between approximately 5 and 10 seconds.
Referring to
In one implementation, the RF power density is held at the level PD2 until the impedance increases to the level it was at prior to the sudden and significant decrease, i.e., Z0. The RF power density is then returned to the initial level PD1. In the implementation shown, the RF power density is then gradually ramped up for a time period 315 from PD2 to PD3. The gradual ramp up in RF power density can start immediately (as shown in
Referring to
By way of illustration, in the context of tissue ablation for the purpose of tubal occlusion, the initial power density PD1 can be approximately 5 watts/cm2. Upon detecting a decrease in the impedance level by approximately 50% or more, the power density is ramped up to PD2 which is in the range of approximately 10-15 watts/cm2. In the implementation shown in
The delivery of RF power in the implementations shown in
In other implementations, e.g., with differently configured electrodes or with differently desired depths of destruction, the power density levels and time periods will vary. However, whatever the RF power density and times, the technique of ramping up RF power density to deal with an unwanted fluid migration while performing tissue ablation with bipolar electrodes and a moisture transport system can be applied. Any fluid that migrates into the vicinity of the electrode, even under the influence of vacuum, will decrease the impedence at the tissue/electrode interface. The fluid can be vaporized to stabilize the impedance and then additional power ramping can be applied, depending on the desired result.
A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.
| Number | Name | Date | Kind |
|---|---|---|---|
| 552832 | Fort | Jan 1896 | A |
| 725731 | Linn | Apr 1903 | A |
| 1620929 | Wallerich | Mar 1927 | A |
| 1827306 | Chapman et al. | Oct 1931 | A |
| 2190383 | Newman | Feb 1940 | A |
| 2347195 | Huff | Apr 1944 | A |
| 2466042 | Reich et al. | Apr 1949 | A |
| 3228398 | Leonard et al. | Jan 1966 | A |
| 3324855 | Heimlich | Jun 1967 | A |
| 3645265 | Majzlin | Feb 1972 | A |
| 3840016 | Lindemann | Oct 1974 | A |
| 3845771 | Vise | Nov 1974 | A |
| 3858586 | Lessen et al. | Jan 1975 | A |
| 3877464 | Vermes | Apr 1975 | A |
| 3924628 | Droegemueller et al. | Dec 1975 | A |
| 3948270 | Hasson | Apr 1976 | A |
| 3967625 | Yoon | Jul 1976 | A |
| 3971378 | Krantz | Jul 1976 | A |
| 4022215 | Benson | May 1977 | A |
| 4057063 | Gieles et al. | Nov 1977 | A |
| 4082096 | Benson | Apr 1978 | A |
| 4094320 | Newton et al. | Jun 1978 | A |
| 4114623 | Meinke et al. | Sep 1978 | A |
| 4158050 | Zipper | Jun 1979 | A |
| 4185618 | Corey | Jan 1980 | A |
| 4233025 | Larson et al. | Nov 1980 | A |
| 4347842 | Beale | Sep 1982 | A |
| 4359454 | Hoffman | Nov 1982 | A |
| 4380238 | Colucci et al. | Apr 1983 | A |
| 4415288 | Gordon et al. | Nov 1983 | A |
| 4449528 | Auth et al. | May 1984 | A |
| 4465072 | Taheri | Aug 1984 | A |
| 4492231 | Auth | Jan 1985 | A |
| 4532483 | Schminke | Jul 1985 | A |
| 4532924 | Auth et al. | Aug 1985 | A |
| 4568326 | Rangaswamy | Feb 1986 | A |
| 4582057 | Auth et al. | Apr 1986 | A |
| 4601698 | Moulding, Jr. | Jul 1986 | A |
| 4606336 | Zeluff | Aug 1986 | A |
| 4628924 | Cimber | Dec 1986 | A |
| 4662383 | Sogawa et al. | May 1987 | A |
| 4676258 | Inokuchi et al. | Jun 1987 | A |
| 4691703 | Auth et al. | Sep 1987 | A |
| 4700701 | Montaldi | Oct 1987 | A |
| 4739759 | Rexroth et al. | Apr 1988 | A |
| 4765331 | Petruzzi et al. | Aug 1988 | A |
| 4788966 | Yoon | Dec 1988 | A |
| 4807620 | Strul et al. | Feb 1989 | A |
| 4832048 | Cohen | May 1989 | A |
| 4865047 | Chou et al. | Sep 1989 | A |
| 4869268 | Yoon | Sep 1989 | A |
| 4946440 | Hall | Aug 1990 | A |
| 4949718 | Neuwirth et al. | Aug 1990 | A |
| 4955377 | Lennox et al. | Sep 1990 | A |
| 4960133 | Hewson | Oct 1990 | A |
| 4961435 | Kitagawa et al. | Oct 1990 | A |
| 4979948 | Geddes et al. | Dec 1990 | A |
| 4981465 | Ballan et al. | Jan 1991 | A |
| 4983177 | Wolf | Jan 1991 | A |
| 5019076 | Yamanashi et al. | May 1991 | A |
| 5026379 | Yoon | Jun 1991 | A |
| 5047028 | Qian | Sep 1991 | A |
| 5057106 | Kasevich et al. | Oct 1991 | A |
| 5065751 | Wolf | Nov 1991 | A |
| 5078717 | Parins et al. | Jan 1992 | A |
| 5084044 | Quint | Jan 1992 | A |
| 5105808 | Neuwirth et al. | Apr 1992 | A |
| 5147353 | Everett | Sep 1992 | A |
| 5159925 | Neuwirth et al. | Nov 1992 | A |
| 5160334 | Billings et al. | Nov 1992 | A |
| 5178148 | Lacoste et al. | Jan 1993 | A |
| 5186181 | Franconi et al. | Feb 1993 | A |
| 5188122 | Phipps et al. | Feb 1993 | A |
| 5188602 | Nichols | Feb 1993 | A |
| 5217473 | Yoon | Jun 1993 | A |
| 5226908 | Yoon | Jul 1993 | A |
| 5242437 | Everett et al. | Sep 1993 | A |
| 5248312 | Langberg | Sep 1993 | A |
| 5263585 | Lawhon et al. | Nov 1993 | A |
| 5277201 | Stern | Jan 1994 | A |
| 5308327 | Heaven et al. | May 1994 | A |
| 5318532 | Frassica | Jun 1994 | A |
| 5322507 | Costello et al. | Jun 1994 | A |
| 5334193 | Nardella | Aug 1994 | A |
| 5334209 | Yoon | Aug 1994 | A |
| 5354295 | Guglielmi et al. | Oct 1994 | A |
| 5357956 | Nardella | Oct 1994 | A |
| 5364393 | Auth et al. | Nov 1994 | A |
| 5370649 | Gardetto et al. | Dec 1994 | A |
| 5374261 | Yoon | Dec 1994 | A |
| 5374283 | Flick | Dec 1994 | A |
| 5380317 | Everett et al. | Jan 1995 | A |
| 5383917 | Desai et al. | Jan 1995 | A |
| 5385544 | Edwards et al. | Jan 1995 | A |
| 5395311 | Andrews | Mar 1995 | A |
| 5405322 | Lennox et al. | Apr 1995 | A |
| 5407071 | Lawhon et al. | Apr 1995 | A |
| 5423808 | Edwards et al. | Jun 1995 | A |
| 5433708 | Nichols et al. | Jul 1995 | A |
| 5437629 | Goldrath | Aug 1995 | A |
| 5443470 | Stern et al. | Aug 1995 | A |
| 5451204 | Yoon | Sep 1995 | A |
| 5474089 | Waynant | Dec 1995 | A |
| 5484400 | Edwards et al. | Jan 1996 | A |
| 5498261 | Strul | Mar 1996 | A |
| 5505730 | Edwards | Apr 1996 | A |
| 5507743 | Edwards et al. | Apr 1996 | A |
| 5514091 | Yoon | May 1996 | A |
| 5540655 | Edwards et al. | Jul 1996 | A |
| 5540681 | Strul et al. | Jul 1996 | A |
| 5540684 | Hassler, Jr. | Jul 1996 | A |
| 5542916 | Hirsch et al. | Aug 1996 | A |
| 5558672 | Edwards et al. | Sep 1996 | A |
| 5562703 | Desai | Oct 1996 | A |
| 5562720 | Stern et al. | Oct 1996 | A |
| 5573533 | Strul | Nov 1996 | A |
| 5575788 | Baker et al. | Nov 1996 | A |
| 5588961 | Leone et al. | Dec 1996 | A |
| 5593404 | Costello et al. | Jan 1997 | A |
| 5599345 | Edwards et al. | Feb 1997 | A |
| 5599346 | Edwards et al. | Feb 1997 | A |
| 5609598 | Laufer et al. | Mar 1997 | A |
| 5613950 | Yoon | Mar 1997 | A |
| 5620481 | Desai et al. | Apr 1997 | A |
| 5649924 | Everett et al. | Jul 1997 | A |
| 5656013 | Yoon | Aug 1997 | A |
| 5658316 | Lamond et al. | Aug 1997 | A |
| 5667520 | Bonutti | Sep 1997 | A |
| 5697882 | Eggers et al. | Dec 1997 | A |
| 5702438 | Avitall | Dec 1997 | A |
| 5716343 | Kriesel et al. | Feb 1998 | A |
| 5722975 | Edwards et al. | Mar 1998 | A |
| 5730136 | Laufer et al. | Mar 1998 | A |
| 5730725 | Yoon | Mar 1998 | A |
| 5733252 | Yoon | Mar 1998 | A |
| 5769880 | Truckai et al. | Jun 1998 | A |
| 5779698 | Clayman et al. | Jul 1998 | A |
| 5797903 | Swanson et al. | Aug 1998 | A |
| 5800482 | Pomeranz et al. | Sep 1998 | A |
| 5807389 | Gardetto et al. | Sep 1998 | A |
| 5810847 | Laufer et al. | Sep 1998 | A |
| 5827271 | Buysse et al. | Oct 1998 | A |
| 5827273 | Edwards | Oct 1998 | A |
| 5843026 | Edwards et al. | Dec 1998 | A |
| 5843121 | Yoon | Dec 1998 | A |
| 5846238 | Jackson et al. | Dec 1998 | A |
| 5865788 | Edwards et al. | Feb 1999 | A |
| 5871469 | Eggers et al. | Feb 1999 | A |
| 5879348 | Owens et al. | Mar 1999 | A |
| 5885601 | Sokal | Mar 1999 | A |
| 5888198 | Eggers et al. | Mar 1999 | A |
| 5891134 | Goble et al. | Apr 1999 | A |
| 5891136 | McGee et al. | Apr 1999 | A |
| 5897551 | Everett et al. | Apr 1999 | A |
| 5897553 | Mulier et al. | Apr 1999 | A |
| 5935123 | Edwards et al. | Aug 1999 | A |
| 5935137 | Saadat et al. | Aug 1999 | A |
| 5938660 | Swartz et al. | Aug 1999 | A |
| 5954715 | Harrington et al. | Sep 1999 | A |
| 5954717 | Behl et al. | Sep 1999 | A |
| 5979446 | Loy | Nov 1999 | A |
| 5997534 | Tu et al. | Dec 1999 | A |
| 6002968 | Edwards | Dec 1999 | A |
| 6014589 | Farley et al. | Jan 2000 | A |
| 6033397 | Laufer et al. | Mar 2000 | A |
| 6036687 | Laufer et al. | Mar 2000 | A |
| 6041260 | Stern et al. | Mar 2000 | A |
| 6042596 | Bonutti | Mar 2000 | A |
| 6047700 | Eggers et al. | Apr 2000 | A |
| 6066139 | Ryan et al. | May 2000 | A |
| 6068613 | Kriesel et al. | May 2000 | A |
| 6068626 | Harrington et al. | May 2000 | A |
| 6071277 | Farley et al. | Jun 2000 | A |
| 6074386 | Goble et al. | Jun 2000 | A |
| 6077257 | Edwards et al. | Jun 2000 | A |
| 6090106 | Goble et al. | Jul 2000 | A |
| 6096052 | Callister et al. | Aug 2000 | A |
| 6112123 | Kelleher et al. | Aug 2000 | A |
| 6117101 | Diederich et al. | Sep 2000 | A |
| 6123702 | Swanson et al. | Sep 2000 | A |
| 6135997 | Laufer et al. | Oct 2000 | A |
| 6139527 | Laufer et al. | Oct 2000 | A |
| 6139546 | Koenig et al. | Oct 2000 | A |
| 6152899 | Farley et al. | Nov 2000 | A |
| 6159207 | Yoon | Dec 2000 | A |
| 6162216 | Guziak et al. | Dec 2000 | A |
| 6164280 | Everett et al. | Dec 2000 | A |
| 6165172 | Farley et al. | Dec 2000 | A |
| 6179832 | Jones et al. | Jan 2001 | B1 |
| 6183468 | Swanson | Feb 2001 | B1 |
| 6193713 | Geistert et al. | Feb 2001 | B1 |
| 6197025 | Grossi et al. | Mar 2001 | B1 |
| 6200312 | Zikorus et al. | Mar 2001 | B1 |
| 6231496 | Wilk et al. | May 2001 | B1 |
| 6231507 | Zikorus et al. | May 2001 | B1 |
| 6234178 | Goble | May 2001 | B1 |
| 6237606 | Zikorus et al. | May 2001 | B1 |
| 6238393 | Mulier et al. | May 2001 | B1 |
| 6245065 | Panescu et al. | Jun 2001 | B1 |
| 6245090 | Gilson et al. | Jun 2001 | B1 |
| 6254601 | Burbank et al. | Jul 2001 | B1 |
| 6258084 | Goldman et al. | Jul 2001 | B1 |
| 6258085 | Eggleston | Jul 2001 | B1 |
| 6263248 | Farley et al. | Jul 2001 | B1 |
| 6277089 | Yoon | Aug 2001 | B1 |
| 6293942 | Goble et al. | Sep 2001 | B1 |
| 6296639 | Truckai et al. | Oct 2001 | B1 |
| 6309384 | Harrington et al. | Oct 2001 | B1 |
| 6315776 | Edwards et al. | Nov 2001 | B1 |
| 6322559 | Daulton et al. | Nov 2001 | B1 |
| 6346102 | Harrington et al. | Feb 2002 | B1 |
| 6352549 | Everett | Mar 2002 | B1 |
| 6364877 | Goble et al. | Apr 2002 | B1 |
| 6369465 | Swanson | Apr 2002 | B1 |
| 6395012 | Yoon et al. | May 2002 | B1 |
| 6398780 | Farley et al. | Jun 2002 | B1 |
| 6402742 | Blewett et al. | Jun 2002 | B1 |
| 6428537 | Swanson | Aug 2002 | B1 |
| 6432116 | Callister et al. | Aug 2002 | B1 |
| 6451015 | Rittman et al. | Sep 2002 | B1 |
| 6475213 | Whayne et al. | Nov 2002 | B1 |
| 6485487 | Sherman | Nov 2002 | B1 |
| 6485500 | Kokish et al. | Nov 2002 | B1 |
| 6490474 | Willis et al. | Dec 2002 | B1 |
| 6508815 | Strul et al. | Jan 2003 | B1 |
| 6554780 | Sampson et al. | Apr 2003 | B1 |
| 6663626 | Truckai et al. | Dec 2003 | B2 |
| 6679269 | Swanson | Jan 2004 | B2 |
| 6712810 | Harrington et al. | Mar 2004 | B2 |
| 6712815 | Sampson et al. | Mar 2004 | B2 |
| 6726682 | Harrington et al. | Apr 2004 | B2 |
| 6743184 | Sampson et al. | Jun 2004 | B2 |
| 6764488 | Burbank et al. | Jul 2004 | B1 |
| 6813520 | Truckai et al. | Nov 2004 | B2 |
| 6964274 | Ryan et al. | Nov 2005 | B1 |
| 7074217 | Strul et al. | Jul 2006 | B2 |
| 7407502 | Strul et al. | Aug 2008 | B2 |
| 7512445 | Truckai et al. | Mar 2009 | B2 |
| 7604633 | Truckai et al. | Oct 2009 | B2 |
| 7717909 | Strul et al. | May 2010 | B2 |
| 7731712 | Sampson et al. | Jun 2010 | B2 |
| 7846160 | Payne et al. | Dec 2010 | B2 |
| 20010041900 | Callister et al. | Nov 2001 | A1 |
| 20020022870 | Truckai et al. | Feb 2002 | A1 |
| 20020029051 | Callister et al. | Mar 2002 | A1 |
| 20020072499 | Clagett | Jun 2002 | A1 |
| 20020072745 | Truckai et al. | Jun 2002 | A1 |
| 20020128649 | Bacher et al. | Sep 2002 | A1 |
| 20020177846 | Mulier et al. | Nov 2002 | A1 |
| 20030093101 | O'Heeron et al. | May 2003 | A1 |
| 20030130711 | Pearson | Jul 2003 | A1 |
| 20030199863 | Swanson | Oct 2003 | A1 |
| 20040054368 | Truckai et al. | Mar 2004 | A1 |
| 20040118166 | Huang et al. | Jun 2004 | A1 |
| 20040172051 | Ravikumar | Sep 2004 | A1 |
| 20040204720 | Harrington et al. | Oct 2004 | A1 |
| 20040255958 | Harrington et al. | Dec 2004 | A1 |
| 20050085880 | Truckai et al. | Apr 2005 | A1 |
| 20050155608 | Pavcnik et al. | Jul 2005 | A1 |
| 20050217680 | Callister et al. | Oct 2005 | A1 |
| 20060095032 | Jackson et al. | May 2006 | A1 |
| 20080071269 | Hilario et al. | Mar 2008 | A1 |
| 20100036372 | Truckai et al. | Feb 2010 | A1 |
| 20100217256 | Strul et al. | Aug 2010 | A1 |
| 20120179155 | Strul et al. | Jul 2012 | A1 |
| Number | Date | Country |
|---|---|---|
| 384246 | Oct 1923 | DE |
| 22 22 820 | Nov 1973 | DE |
| 4001086 | Jan 1990 | DE |
| 0 056 178 | Apr 1981 | EP |
| 0 584 930 | Jul 1993 | EP |
| 1 400 182 | Jun 2004 | EP |
| 774.550 | Sep 1934 | FR |
| 70.43012 | Jun 1972 | FR |
| 2115706 | Jul 1972 | FR |
| 2317566 | Jan 1998 | GB |
| 48-67586 | Sep 1973 | JP |
| 58-32756 | Feb 1983 | JP |
| 63-318934 | Dec 1988 | JP |
| WO 9219145 | Nov 1992 | WO |
| WO 9400178 | Jan 1994 | WO |
| WO 9407445 | Apr 1994 | WO |
| WO 9410948 | May 1994 | WO |
| WO 9423794 | Oct 1994 | WO |
| WO 9504385 | Feb 1995 | WO |
| WO 9505869 | Mar 1995 | WO |
| WO 9507664 | Mar 1995 | WO |
| WO 9510326 | Apr 1995 | WO |
| 9600042 | Jan 1996 | WO |
| 9712569 | Apr 1997 | WO |
| 9741785 | Nov 1997 | WO |
| 9838932 | Sep 1998 | WO |
| WO 9958070 | Nov 1999 | WO |
| WO 0197897 | Dec 2001 | WO |
| Entry |
|---|
| D.E. Haines et al., “Observations on Electrode-Tissue Interface Temperature and Effect on Electrical Impedance During Radiofrequency Ablation of Ventricular Myocardium,” Circulation, vol. 82, No. 3, Sep. 1990, pp. 1034-1038. |
| C. Nibley et al., “Prevention of Impedance Rise During Radiofrequency Current Catheter Ablation by Intra-Electrode Tip Chilling,” Circulation [Abstracts From the 67th Scientific Sessions, Dallas Convention Center, Dallas, Texas, Nov. 14-17, 1994], vol. 90, No. 4, Part 2, Oct. 1994, p. 460. |
| W.M. Jackman et al., “Radiofrequency Current Directed Across the Mitral Anulus With a Bipolar Epicardial-Endocardial Catheter Electrode Configuration in Dogs,” Circulation, vol. 78, No. 5, Nov. 1988, pp. 1288-1298. |
| “Essure: the non-incisional approach to permanent birth control”, Patient Information Booklet, ©2004 by Conceptus Incorporated. |
| “Tubal Ligation—Fimbriectomy: Tubal Reversal is Possible after Fimbriectomy” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Internet: <URL:http://www.tubal-reversal.net/print/printer-friendly-tubal—ligation—fimbriectomy.htm>. |
| “Tubal Ligation and Resection: Tubal Ligation by Parkland and Irving Methods” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved on Oct. 19, 2004] Retrieved from the Interent: <URL: http://www.tubal-reversal.net/print/printer-friendly-tubal—ligation—resection.htm>. |
| “Tubal Ligation—Tubal Ring or Clip: Tubal Ligation with Tubal Rings or Tubal Clips” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.tubal-reversal.net/tubal—ligation-tubal—ring-tubal—clip.htm>. |
| “Tubal Ligation—Pomeroy Technique: Pomeroy Tubal Ligation and Resection” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004 [retrieved Oct. 19, 2004] Retrieved from the Internet: <http://www.tubal-reversal.net/print/printer-friendly-tubal—ligation—Pomeroy.htm >. |
| “Tubal Ligation Methods: Coagulation Methods of Tubal Ligation” Datasheet [on-line] Chapel Hill Tubal Reversal Center, 2004, [retrieved Oct. 19, 2004] Retrieved from the Internet: <http://www.tubal-reversal.net/tubal—ligation—coagulation.htm >. |
| “Essure, Permanent Birth Control by Conceptus: What is Essure?” Product Information Sheet [on-line] [retrieved Oct. 19, 2004] Retrieved from the Internet: <URL: http://www.essure.com/consumer/c—what—is—essure.aspx>. |
| METI-MyriadLase, SteriLase, Powerpoint Presentation, published at least as of Jun. 13, 2006, 6 pp. |
| Adiana options for women—how it works. (Dec. 31, 2005). Retrieved from http://web.archive.org/web/20051124001429/www.adiana.com/products.sub.--h- ow.php. |
| First Request for Ex Partes Reexamination of U.S. Patent No. 5,769,880, filed Jul. 27, 1999. |
| Second Request for Ex Partes Reexamination of U.S. Patent No. 5,769,880, filed Nov. 22, 2000. |
| Number | Date | Country | |
|---|---|---|---|
| 20080071257 A1 | Mar 2008 | US |
